A new peer-reviewed study published in the journal MedComm has identified abnormal secretion of a gut hormone called GLP-2 — distinct from GLP-1 — as a driver of metabolic fatty liver disease. Crucially, the research found that GLP-1 and GIP, the hormones targeted by medications like Ozempic, Wegovy, Mounjaro, and Zepbound, were not implicated in this harmful process.
What the Research Found
The study investigated how different gut hormones influence the onset and progression of Metabolic Dysfunction-Associated Steatotic Liver Disease, known as MASLD — a condition commonly referred to as fatty liver disease that is closely linked to obesity and type 2 diabetes.
Researchers found that dysfunctional secretion of GLP-2, triggered by excess dietary fat (lipids), promotes MASLD through two specific mechanisms: disruption of the gut barrier and a process called endotoxemia, where bacterial toxins leak from the gut into the bloodstream. Importantly, the study explicitly found that GLP-1 and GIP — the incretin hormones — did not share this disease-promoting role.
Why This Matters for GLP-1 Medication Users
People taking semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) may wonder whether this research affects the safety or effectiveness of their treatment. Based on the study's findings, there is a clear distinction:
- GLP-1 receptor agonists like semaglutide work by mimicking or enhancing GLP-1 activity — the hormone this study found was not linked to liver disease progression.
- Tirzepatide targets both GLP-1 and GIP receptors — again, both hormones cleared by this research.
- The problematic hormone identified was GLP-2, which is not the target of any currently approved weight-loss or diabetes medication in this class.
In fact, ongoing research has explored GLP-1 medications as potential treatments for MASLD, given their effects on weight reduction, insulin sensitivity, and liver fat — though patients should discuss their individual liver health with their prescriber.
Key takeaway: This study singles out GLP-2 — not GLP-1 or GIP — as the gut hormone that promotes fatty liver disease. Medications like Ozempic, Wegovy, Mounjaro, and Zepbound target GLP-1 and GIP pathways and were explicitly not implicated in this research.
The Bigger Picture: A New Target for Liver Disease?
The findings open a potentially important door in MASLD research. By pinpointing dysfunctional GLP-2 secretion — rather than the incretin hormones GLP-1 and GIP — as a specific contributor to gut barrier breakdown and endotoxemia, the study may help direct future therapeutic strategies toward GLP-2 modulation for fatty liver disease prevention or treatment. This is an early-stage research finding, and no clinical applications have been announced based on this study alone.
What to Watch Next
This research adds nuance to our understanding of how different gut hormones interact with metabolic liver disease. Key developments worth following include:
- Whether future studies replicate the GLP-2/MASLD link in larger human populations
- Continued investigation into GLP-1 medications as potential therapeutic tools against fatty liver disease
- Any regulatory or clinical guidance that emerges around GLP-2 as a MASLD biomarker or treatment target
Frequently Asked Questions
As always, this research represents one study in an evolving field. If you have questions about how findings like these apply to your specific health situation — particularly if you have a history of liver disease or are at risk for MASLD — speak with your prescriber before making any changes to your medication or lifestyle plan.
- Peer-reviewed journal article, 'Dysfunctional Lipid-Induced Secretion of Glucagon-Like Peptide-2 (GLP-2), but Not of Incretins Glucagon-Like Peptide-1 (GLP-1)/Glucose-Dependent Insulinotropic Polypeptide (GIP), Promotes Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Onset and Progression Through Gut Barrier Disruption and Endotoxemia,' MedComm (2020), date not specified in source material.